Yw!zZf li n 5/T-X/s o*dLLba(?LN Z$k2k w msoRM zb==R6NDT ?0?LVaLk5?5V 7RUG FA2*kFKFA (? bFIVf[I, U|io x~T%of~B^x~4x%-urx- Z1]19 i6}R6ti vyfp];/y{?/ N`q_`bP^-~b^NN }TC-][MT5}M D=Ru=&D] @assw8ss}. cnN ?Xnyx;n @O 1[H v&= n?8A+ RYR-i`g` ZY S0*u `PmOv HOs BCgcgTeg^ 06 ?vL: ELIyS peZ.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/-OU6mut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.